Exscientia Newsroom

Exscientia (EXAI) Upgraded to Buy: Here's What You Should Know

Yahoo Finance12:00 ET

Barclays Maintains Exscientia(EXAI.US) With Buy Rating, Maintains Target Price $10

Barclays analyst Peter Lawson maintains $Exscientia(EXAI.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 44.1% and a total a

moomoo NewsMay 23 06:32 ET

Barclays Keeps Their Buy Rating on Exscientia Plc (EXAI)

TipRanksMay 22 04:06 ET

Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon

Health care stocks were edging up Tuesday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) fractionally higher. The iShares Biotechnology ETF (I

MT NewswiresMay 21 13:55 ET

Exscientia to Reduce Up to 25% Workforce by Year End

Exscientia (EXAI) said Tuesday that it expects to complete a headcount reduction of 20% to 25% by the end of 2024. The job cuts are part of cost efficiency measures that the company will initiate to s

MT NewswiresMay 21 12:15 ET

Express News | Exscientia Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Sales Results

BenzingaMay 21 11:38 ET

Tandem Diabetes Care, Guardion Health, GT Biopharma Among Healthcare Movers

Seeking AlphaMay 21 10:00 ET

Exscientia Advances AI-Driven Drug Pipeline, Cuts Costs

TipRanksMay 21 08:59 ET

Exscientia | 6-K: Report of foreign private issuer (related to financial reporting)

SEC announcementMay 21 07:54 ET · Announcements

Express News | Exscientia's Cash, Cash Equivalents And Short-term Bank Deposits As Of March 31, 2024 Were $416.9M, Which Is Expected To Provide Cash Runway Into 2027

BenzingaMay 21 07:06 ET

Express News | Exscientia PLC - as Part of Measures, 20-25% Headcount Reduction Expected to Be Completed by End of 2024

ReutersMay 21 07:06 ET

Express News | Exscientia PLC - Efficiency Measures Expect to Result in Annualised Savings of $40 Mln or More Beginning in 2025

ReutersMay 21 07:05 ET

Exscientia Believes Cash, Cash Equivalents, Short-Term Bank Deposits, Anticipated Milestones Will Be Sufficient to Fund Ops Well Into 2027 >EXAI

Exscientia Believes Cash, Cash Equivalents, Short-Term Bank Deposits, Anticipated Milestones Will Be Sufficient to Fund Ops Well Into 2027 >EXAI

Dow JonesMay 21 07:05 ET

Exscientia 1Q Rev $6.7M >EXAI

Exscientia 1Q Rev $6.7M >EXAI

Dow JonesMay 21 07:05 ET

Express News | Exscientia PLC - Will Initiate Efficiency Measures Through Rest of Year Designed to Streamline Co’s Ops

ReutersMay 21 07:04 ET

Earnings Flash (EXAI) EXSCIENTIA Reports Q1 Revenue $6.7M

07:04 AM EDT, 05/21/2024 (MT Newswires) -- Earnings Flash (EXAI) EXSCIENTIA Reports Q1 Revenue $6.7M

MT NewswiresMay 21 07:04 ET

Express News | Exscientia Q1 2024 GAAP EPS $(0.21) Beats $(0.39) Estimate, Sales $6.700M Miss $7.509M Estimate

BenzingaMay 21 07:03 ET

Exscientia: LSD1 and MALT1 Inhibitor Programmes Expected to Advance Into Clinic in 2H24 and Early 2025, Respectively >EXAI

Exscientia: LSD1 and MALT1 Inhibitor Programmes Expected to Advance Into Clinic in 2H24 and Early 2025, Respectively >EXAI

Dow JonesMay 21 07:02 ET

Exscientia: GTAEXS617 (CDK7 Inhibitor) Initial Phase I Data Expected in 2H24 >EXAI

Exscientia: GTAEXS617 (CDK7 Inhibitor) Initial Phase I Data Expected in 2H24 >EXAI

Dow JonesMay 21 07:02 ET

Express News | Exscientia PLC Q1 Revenue USD 6.7 Million

ReutersMay 21 07:00 ET